Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma

Cancer Management and Research

Volumn 7, Issue , 2015, Pages 65-73

  Gunnarsson, Orvar ^a   Pfanzelter, Nicklas R ^b   Cohen, Roger B ^a   Keefe, Stephen M ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Axitinib; Drug safety; Renal cell carcinoma; Side effects

Indexed keywords

AXITINIB; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; VANDETANIB;

ADVANCED CANCER; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER SURVIVAL; CAPILLARY DENSITY; COMPARATIVE EFFECTIVENESS; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHONIA; EPISTAXIS; FATIGUE; HAND FOOT SYNDROME; HEMATURIA; HUMAN; HYPERTENSION; HYPOTHYROIDISM; IC50; KIDNEY CARCINOMA; KIDNEY METASTASIS; LYMPHOCYTOPENIA; MULTICENTER STUDY (TOPIC); NAUSEA; NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; STEADY STATE; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; VOMITING;

EID: 84922783304     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S74202     Document Type: Review

References (48)

1. Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangio­genesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol. 2005;23(24): 5474–5483.
2. Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothe­lial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol. 2004;165(1):35–52.
3. Hu-Lowe DD, Zou HY, Grazzini ML, et al. Nonclinical antiangio­genesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res. 2008;14(22):7272–7283.
4. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9(1):327–337.
5. Kumar R, Knick VB, Rudolph SK, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther. 2007;6(7):2012–2021.
6. Ahmad T, Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res. 2004;10(18 Pt 2):6388S–6392S.
7. Tortorici MA, Toh M, Rahavendran SV, et al. Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics. Invest New Drugs. 2011;29(6):1370–1380.
8. Rixe O, Bukowski RM, Michaelson MD, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol. 2007;8(11):975–984.
9. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20(1):289–296.
10. Escudier B, Roigas J, Gillessen S, et al. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol. 2009;27(25):4068–4075.
11. Hutson TE, Davis ID, Machiels JH, et al. Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor [abstract]. J Clin Oncol. 2008;26(15S Suppl):abstract 5046.
12. Rini BI, de La Motte Rouge T, Harzstark AL, et al. Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib. Clin Genitourin Cancer. 2013;11(2):107–114.
13. Rini BI, Wilding G, Hudes G, et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol. 2009;27(27):4462–4468.
14. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931–1939.
15. United States Food and Drug Administration [webpage on the Internet]. Axitinib. Silver Spring, MD: US Food and Drug Administration; 2012. Available from: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm289439.htm. Accessed February 22, 2014.
16. Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013;14(6):552–562.
17. Hotte SJ, Bjarnason GA, Heng DY, et al. Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma. Curr Oncol. 2011;18 Suppl 2:S11–S19.
18. Hutson TE, Lesovoy V, Al-Shukri S, et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol. 2013;14(13): 1287–1294.
19. Karam JA, Devine CE, Urbauer DL, et al. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. Eur Urol. Epub February 7, 2014.
20. Rini BI, Schiller JH, Fruehauf JP, et al. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res. 2011;17(11):3841–3849.
21. Jonasch E, Bair A, Chen Y, Rini BI. Axitinib with or without dose titra­tion as first-line therapy for metastatic renal cell carcinoma (mRCC) [abstract]. J Clin Oncol. 2010;28(Suppl 15S):abstract TPS235.
22. Rini BI, Garrett M, Poland B, et al. Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis. J Clin Pharmacol. 2013;53(5):491–504.
23. Qi WX, He AN, Shen Z, Yao Y. Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis. Br J Clin Pharmacol. 2013; 76(3):348–357.
24. Rini BI, Melichar B, Ueda T, et al. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol. 2013;14(12):1233–1242.
25. Rini BI, Escudier BJ, Michaelson MD, et al. Phase III AXIS trial for second-line metastatic renal cell carcinoma (mRCC): effect of prior first-line treatment duration and axitinib dose titration on axitinib efficacy [abstract]. J Clin Oncol. 2012;30 Suppl 5:abstract 354.
26. Mukohara T, Nakajima H, Mukai H, et al. Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients. Cancer Sci. 2010; 101(4):963–968.
27. Cella D, Escudier B, Rini B, et al. Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial. Br J Cancer. 2013;108(8):1571–1578.
28. Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008;26(29):4708–4713.
29. Infante JR, Reid TR, Cohn AL, et al. Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic col­orectal cancer: a randomized phase 2 study. Cancer. 2013;119(14): 2555–2563.
30. Rugo HS, Stopeck AT, Joy AA, et al. Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. J Clin Oncol. 2011;29(18):2459–2465.
31. Kindler HL, Ioka T, Richel DJ, et al. Axitinib plus gemcitabine ver­sus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol. 2011;12(3):256–262.
32. Belani CP, Yamamoto N, Bondarenko IM, et al. Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer. BMC Cancer. 2014;14:290.
33. Twelves C, Chmielowska E, Havel L, et al. Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer. Ann Oncol. 2014;25(1):132–138.
34. Les essais cliniques. Registre des essais cliniques français en can­cérologie [Clinical trials. Register of French cancer clinical trials] [webpage on the Internet]. Paris: Insitut National Du Cancer; 2014. Available from: http://www.e-cancer.fr/en/recherche/recherche-clinique/registre-des-essais-cliniques/registre-des-essais-cliniques/details-etude?idFiche=2256. Accessed January 5, 2015. French.
35. Escudier B, Pluzanska A, Koralewski P, et al; AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370(9605):2103–2111.
36. Escudier BJ, Bellmunt J, Negrier S, et al. Final results of the phase III randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-a2a (IFN) in metastatic renal cell carcinoma (mRCC) [abstract]. J Clin Oncol. 2009;27(15 Suppl):abstract 5020.
37. Escudier B, Bellmunt J, Négrier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010; 28(13):2144–2150.
38. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with meta­static renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008;26(33): 5422–5428.
39. Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010;28(13):2137–2143.
40. Hudes G, Carducci M, Tomczak P, et al; Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271–2281.
41. Motzer RJ, Escudier B, Oudard S, et al; RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637): 449–456.
42. Motzer RJ, Escudier B, Oudard S, et al; RECORD-1 Study Group. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010;116(18): 4256–4265.
43. Escudier B, Eisen T, Stadler WM, et al; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125–134.
44. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treat­ment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009;27(20):3312–3318.
45. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2): 115–124.
46. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22): 3584–3590.
47. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061–1068.
48. Sternberg CN, Hawkins RE, Wagstaff J, et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer. 2013;49(6):1287–1296.